Par Health Recalls Two Lots of Brevital Sodium Due to Particulate Matter

Par Health has initiated a voluntary recall of two lots of its Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) across the United States. The reason for the recall is the presence of cellulose particulate matter identified within the product.

Methohexital Sodium is used as an anesthetic agent. The presence of particulate matter in injectable products can pose risks to patient safety, particularly with intravenous administration. Such particles could potentially lead to vascular blockages or other adverse effects.

Par Health is instructing healthcare professionals to discontinue the use of the affected lots immediately and to return them according to established procedures. The company stated it has not received any reports of adverse events associated with this recall.

The lots subject to this recall are LOT 326021 and LOT 326381. Par Health has notified the U.S. Food and Drug Administration (FDA) and is informing its customers of the recall through direct communication.